Anzeige
Mehr »
Login
Montag, 13.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Die 1 Billionen Dollar Mine: Power Nickels Weg zur globalen Dominanz!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
372 Leser
Artikel bewerten:
(2)

NDR Norddeutscher Rundfunk: Klusmann Report confirms: Russian payments made to documentary filmmaker were unknown to NDR

Finanznachrichten News

HAMBURG, Germany, Jan. 25, 2024 /PRNewswire/ -- Picture is available at AP -

The investigation into the Hubert Seipel case commissioned by NDR has been completed. The report issued by former Spiegel editor-in-chief Steffen Klusmann confirms misconduct on the part of the freelance author. Hubert Seipel should have disclosed his sponsorship contracts to NDR. Regarding NDR and ARD, there was no evidence that those involved in the production knew about the Russian payments or benefited financially from them.

The allegation that Seipel had the biopic "Ich Putin" [I, Putin] "approved" by the Kremlin before it was broadcast has also not been confirmed. To this day, Hubert Seipel maintains that his Russian sponsor did not influence his book projects or the films. However, according to the report, the author was "open to bribery through proximity." Seipel lost the necessary distance due to his exclusive access to Putin. The suspicion that NDR disregarded a "warning" about Seipel or Russian influence has also not been confirmed, as there was no concrete and substantiated warning.

Although there was no evidence of NDR employees neglecting their duties, the report concludes that Seipel had been heavily wooed over the years and had not received enough critical scrutiny.

Joachim Knuth, Director-General at NDR: "I want to thank the team for the report. It clearly shows that nobody at NDR knew about the money flowing to Hubert Seipel from Russia because the author had concealed it, and there were no other indications. The report also provides us with valuable suggestions. We will strike a clearer balance between closeness and distance to protagonists in large biographies, as well as between skepticism and enthusiasm - even more so in the case of particularly strong material. I have now asked three colleagues from the editorial and legal departments to take up the suggestions in Steffen Klusmann's report and put them into concrete terms for us."

About the report

The Klusmann Report traces what Seipel specifically worked on between 2009 and 2017 and the conditions under which documentaries and book projects on Russia, among other things, came about. The main focus is on the documentary "Ich, Putin" [I, Putin] (2012) and "Putin - Das Interview" [Putin - The Interview] (2014). Dr. Michael Kühn, NDR's chief legal advisor, who is also responsible for compliance issues, shed light on the legal dimension of the Seipel case for the report. Klusmann and Kühn reviewed numerous documents for the report, journalistically assessed Seipel's films, and contacted around 40 people. Among them was Hubert Seipel himself, who answered questions in writing. Russia expert Dr. Gesine Dornblüth examined Seipel's films to contextualize them in the period they were produced. Dornblüth worked as a Moscow correspondent for Deutschlandradio [Radio Germany] from 2012 to 2017.

The Klusmann Report and Dr. Gesine Dornblüth's expert opinion on Seipel's films are available on the NDR website.

Contact:

Norddeutscher Rundfunk
Unternehmenskommunikation
Presse und Kommunikation
Mail: presse@ndr.de
www.twitter.com/NDRpresse
+49(0)40/41562300

Cision View original content:https://www.prnewswire.co.uk/news-releases/klusmann-report-confirms-russian-payments-made-to-documentary-filmmaker-were-unknown-to-ndr-302044886.html

© 2024 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.